Entrada Therapeutics

NMQ:TRDA · US29384C1080

BiotechnologySmall

360

Value33

Profit price18

Cash yield1

Sales & asset price79

Price/Sales85

Price/Book72

Quality49

Returns on capital56

Return on Capital59

Cash Return on Capital51

Return on Equity58

Profit margins21

Cash backing50

Accruals86

Owner Earnings Margin14

Growth39

Sales growth34

Profit growth43

Reinvestment1

Price momentum18

Safety46

Debt load35

Debt serviceability28

Refinancing55

Debt Payback1

Liquidity71

Sentiment54

Analyst ratings58

Expectations trend51

Opinion Changes26

Price Target Upside76

Market mood78

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Entrada Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2016

Employees185

Websiteentradatx.com

ISINUS29384C1080

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

OphthalmologyGeneticsNeurologyImmunologyCentral Nervous SystemGenetic DisorderOncologyBiotechnologyEmergency MedicineHealth CareMedical

Description

Entrada Therapeutics, Inc. (Entrada) operates as a clinical-stage biopharmaceutical company. The company transforms the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inacc…

Analysis

Hope premium

Entrada Therapeutics, Inc. carries what we call a hope premium: an average business trading at an ambitious price.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

100

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Entrada Therapeutics with its peers

Pyxis Oncology

NSQ:PYXS

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

PepGen

NSQ:PEPG

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Beam Therapeutics

NSQ:BEAM

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Dyne Therapeutics

NSQ:DYN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Candel Therapeutics

NMQ:CADL

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Annexon

NSQ:ANNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →